Myriad Genetics (MYGN) Peer Comparison

$3.11

$-0.08 (-2.36%)

As on 28-Aug-2026 13:35EDT

Market cap

$306 Mln

Revenue (TTM)

$807 Mln

P/E Ratio

--

P/B Ratio

1

Div. Yield

0 %

Edit

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	306	12,753	10,906	10,222	9,762
Revenue ($ Mln)	807	1,505	613	785	2,589
Net Profit ($ Mln)	-112.60	160.59	-188.05	41.54	222.40
Net Margin (%)	-13.96	10.67	-30.68	5.29	8.59
RoE (%)	-33.52	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.57	44.47
Price-To-Book	1.01	8.41	16.38	4.84	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	806.60	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	251.40	483.98	127.96	384.30	1,245.50
Gross Profit	576.60	942.44	393.22	347.62	1,343.60
Operating Expenses	653.80	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-98.60	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-111.80	203.83	-192.83	52.15	350.40
Provision for Tax	0.80	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-112.60	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	303.90	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	204.30	210.18	135.71	705.49	2,116.80
Current Liabilities	130.70	233.78	102.33	132.66	961.30
Total Liabilities	706.60	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	349.90	630.60	404.74	1,749.63	7,231.50
Current Assets	289.00	1,344.12	515.78	1,200.55	3,020.50
Total Assets	706.60	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	210.50	212.71	102.84	690.94	1,203.70
Net Current Assets	158.30	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	1.80	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-27.40	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	64.20	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-51.56	11.76	-22.53	1.79	8.98
ROE (%)	-33.52	10.86	-28.10	1.97	3.04
ROA (%)	-13.68	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-11.83	13.63	-30.58	9.87	-5.99
Net Margin (%)	-13.96	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	-3.16	17.55	41.55	16.49	1.37
EBIT Growth (%)	77.09	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	71.51	8.72	-102.66	400.42	-30.32
EPS Growth (%)	72.02	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-23.60	17.33	-12.65	2.16	2.19

Valuation Ratios

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-1.57	68.93	-34.59	189.42	--
Price / Book Value	1.56	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-1.92	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.40	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.02	0.01	0.00	0.01	0.06
Current Ratio	2.21	5.75	5.04	9.05	3.14
Quick Ratio	1.98	3.86	4.46	7.64	2.33
Interest Coverage	-5.82	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Myriad Genetics (MYGN)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	13.58	12.65	22.67	20.09	17.06
Asset Turnover	0.98	0.74	0.59	0.26	0.24
Receivable days	52.38	46.54	60.95	72.41	65.39
Inventory Days	42.80	331.92	193.84	146.53	221.09
Payable days	45.90	26.16	60.19	29.05	37.02
Cash Conversion Cycle	49.29	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly